Advertisement

Related Videos

Welcome and Introduction to Vi3C

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Jul
17
Today In Oncology
Virtual Sustained Counseling and Tobacco Treatment Improve Quit Rates for Patients With Cancer in Community Settings
Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
Digital Check-ins May Improve Outcomes in Patients Undergoing Treatment for Advanced Cancer
How Do Surgical Ovarian Cancer Prevention Strategies Compare for Sexual Function?
ENDURANCE Trial in Newly Diagnosed Myeloma No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo